777 related articles for article (PubMed ID: 17393458)
1. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
[TBL] [Abstract][Full Text] [Related]
2. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
[TBL] [Abstract][Full Text] [Related]
3. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
5. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
Li EK; Tam LS; Zhu TY; Li M; Kwok CL; Li TK; Leung YY; Wong KC; Szeto CC
Rheumatology (Oxford); 2009 Aug; 48(8):892-8. PubMed ID: 19478041
[TBL] [Abstract][Full Text] [Related]
6. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response.
Jónsdóttir T; Gunnarsson I; Risselada A; Henriksson EW; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2008 Mar; 67(3):330-4. PubMed ID: 17827182
[TBL] [Abstract][Full Text] [Related]
7. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
[TBL] [Abstract][Full Text] [Related]
8. Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria.
Gunnarsson I; Sundelin B; Heimbürger M; Forslid J; van Vollenhoven R; Lundberg I; Jacobson SH
J Rheumatol; 2002 Apr; 29(4):693-9. PubMed ID: 11950009
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
[TBL] [Abstract][Full Text] [Related]
10. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
[TBL] [Abstract][Full Text] [Related]
11. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.
Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM
Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003
[TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy for childhood-onset systemic lupus erythematosus.
Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
[TBL] [Abstract][Full Text] [Related]
13. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
[TBL] [Abstract][Full Text] [Related]
17. [Significance of serum anti-Clq Ab in evaluation of lupus nephritis activity and its curative effects of pharmacotherapy on lupus nephritis].
Cai XY; Yang XY; Chen XH; Liang LQ; Guan MM; Qin SG; Fu JZ
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(17):1436-9. PubMed ID: 15500738
[TBL] [Abstract][Full Text] [Related]
18. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
[TBL] [Abstract][Full Text] [Related]
19. Longterm followup of childhood lupus nephritis.
Hagelberg S; Lee Y; Bargman J; Mah G; Schneider R; Laskin C; Eddy A; Gladman D; Urowitz M; Hebert D; Silverman E
J Rheumatol; 2002 Dec; 29(12):2635-42. PubMed ID: 12465165
[TBL] [Abstract][Full Text] [Related]
20. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
